A common artificial sweetener may trigger insulin spikes that lead to the build up of fatty plaques in the arteries, ...

Recent research suggests that select athletes with cardiovascular abnormalities may be able to safely participate in ...

Olpasiran reduces oxidized phospholipids but not inflammation in cardiovascular disease—what does this mean for clinical care ...

A phase 2 trial shows that olpasiran, an RNA-based therapy, reduces lipoprotein(a) [Lp(a)] levels by more than 95% in ...

ApoB is emerging as a crucial piece of the heart health puzzle, even as sophisticated machines whir and beep with promises of ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

A study found that typical cholesterol exams could be missing an important indicator of heart disease risk in certain people.

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

Analysis by Mount Sinai researcher from First-of-its kind global trial could lead to future therapies to prevent deadly ...

Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk ...